DrugPatentWatch Database Preview
Drugs in Development Information for Urapidil
What is the drug development status for Urapidil?
Urapidil is an investigational drug.
There have been 12 clinical trials for Urapidil.
The most recent clinical trial was a Phase 1 trial, which was initiated on June 15th 2017.
The most common disease conditions in clinical trials are Hypertension, Stroke, and Hemorrhage. The leading clinical trial sponsors are University Hospital, Strasbourg, France, The George Institute, and National Health and Medical Research Council, Australia.
There are nine hundred and three US patents protecting this investigational drug and seven international patents.
Summary for Urapidil
| US Patents | 903 |
| International Patents | 7,878 |
| US Patent Applications | 1,687 |
| WIPO Patent Applications | 1,032 |
| Japanese Patent Applications | 8 |
| Clinical Trial Progress | Phase 1 (2017-06-15) |
| Vendors | 59 |
Recent Clinical Trials for Urapidil
| Title | Sponsor | Phase |
|---|---|---|
| Intensive Ambulance-delivered Blood Pressure Reduction in Hyper-Acute Stroke Trial | First Affiliated Hospital of Chengdu Medical College | Phase 3 |
| Intensive Ambulance-delivered Blood Pressure Reduction in Hyper-Acute Stroke Trial | Shanghai East Hospital | Phase 3 |
| Intensive Ambulance-delivered Blood Pressure Reduction in Hyper-Acute Stroke Trial | The George Institute for Global Health, China | Phase 3 |
Clinical Trial Summary for Urapidil
Top disease conditions for Urapidil
Top clinical trial sponsors for Urapidil
US Patents for Urapidil
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Urapidil | Start Trial | Double-acylated GLP-1 derivatives | Novo Nordisk A/S (Bagsvaerd, DK) | Start Trial |
| Urapidil | Start Trial | Double-acylated GLP-1 derivatives | Novo Nordisk A/S (Bagsvaerd, DK) | Start Trial |
| Urapidil | Start Trial | Derivatives of GLP-1 like peptides, and uses thereof | Novo Nordisk A/S (Bagsvaerd, DK) | Start Trial |
| Urapidil | Start Trial | Ultra-pure agonists of guanylate cyclase C, method of making and using same | SYNERGY PHARMACEUTICALS, INC. (New York, NY) | Start Trial |
| Urapidil | Start Trial | Compositions containing polymeric, ionic compounds comprising imidazolium groups | BASF SE (Ludwigshafen, DE) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Urapidil
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Urapidil | China | 104519902 | 2032-05-08 | Start Trial |
| Urapidil | European Patent Office | 2846823 | 2032-05-08 | Start Trial |
| Urapidil | Japan | 2015517477 | 2032-05-08 | Start Trial |
| Urapidil | Japan | 6250034 | 2032-05-08 | Start Trial |
| Urapidil | World Intellectual Property Organization (WIPO) | 2013167454 | 2032-05-08 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
